about
Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgerySirolimus Increases T-Cell Abundance in the Sun Exposed Skin of Kidney Transplant RecipientsEffect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modellingDevelopment and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations.Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery.Pharmacokinetic considerations relating to tacrolimus dosing in the elderly.Exposure-effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritisPopulation Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.Predictors of new onset diabetes after renal transplantation.Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients.Therapeutic monitoring of mycophenolate in transplantation: is it justified?Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.Once- versus twice-daily tacrolimus: are the formulations truly equivalent?Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation.Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.Genetics and nonmelanoma skin cancer in kidney transplant recipients.Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.A Population Pharmacokinetic Model of Gentamicin in Pediatric Oncology Patients To Facilitate Personalized Dosing.Development of Improved Dosing Regimens for Mycophenolate Mofetil Based on Population Pharmacokinetic Analyses in Adults with Lupus Nephritis.Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?Patterns in use and costs of conventional and biologic disease-modifying anti-rheumatic drugs in Australia.Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy.Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.Gentamicin Pharmacokinetics and Monitoring in Pediatric Patients with Febrile Neutropenia.Gentamicin Pharmacokinetics and Monitoring in Pediatric Febrile Neutropenic Patients.Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance.Evaluation of the mycophenolic acid exposure estimation methods used in the APOMYGERE, FDCC, and Opticept trials.Antimicrobial stewardship in paediatric oncology: Impact on optimising gentamicin use in febrile neutropenia.Bayesian forecasting and prediction of tacrolimus concentrations in pediatric liver and adult renal transplant recipients.Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation.Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.Expression of Bcl-xL and Mcl-1 in the nonmelanoma skin cancers of renal transplant recipients.Evaluation of limited sampling strategies for mycophenolic acid after mycophenolate mofetil intake in adult kidney transplant recipients.Tacrolimus pharmacokinetics after kidney transplantation--Influence of changes in haematocrit and steroid dose.Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation.
P50
Q31144236-9122A4C9-7BFB-4822-98A2-881E5C9304B1Q33873997-2A5934BE-193D-433A-9C3D-1687F1994CFCQ34099716-04636F6D-36C3-4D09-9E16-D8226B2D8DBFQ34102899-AAF8790E-65D7-4873-8872-0398503ED1DAQ34571036-4FC6F9B6-2B29-45F0-9745-F5E73ED7FE80Q34965569-E4DC57F1-26B4-4268-90D1-8E909F404FABQ35827409-373CCDA6-6364-464A-8CEF-7C3F3AC6EC67Q36204404-275820C4-A23A-4C30-A869-F1C74A61D094Q36243640-94C93818-1E70-4D4D-9676-FCBA15BC55C5Q36438971-B9E5D435-46C5-4E95-9E82-4922CF23C0B0Q36736407-6861EF22-00BE-47B1-A3D3-319658325C00Q36933449-130A282C-E3B4-496C-A13C-51B47A3780C3Q37411261-C02EAD05-C2FD-4B5B-BBA4-33E7EFC0A770Q37824525-0ECA240E-50F3-4339-895D-B3743D6C104AQ37921280-BE3A8AE7-2692-4587-80EB-D0BD25618E4EQ37956717-354634C2-22AE-4E3B-A2B3-6B4F66A3B990Q38047203-2A8C29EC-0F5F-4129-B6CA-CA9F77CFE344Q38087925-1E76B0DE-5F2E-4862-81DE-4516994B4028Q38170321-9B2024CC-C850-408E-8D5C-5677CE7BE389Q38208983-2C794F11-F149-4805-AC37-34E3681BE5E4Q38330222-B5FCA68C-E19B-47CE-8681-6BA01E86EB62Q38514054-5BAFE249-5164-422D-A9ED-FB996C4D5B6EQ38680501-41AB6005-6A0B-4D76-866A-CEDD55B591F3Q38768108-35BB0592-3D40-4FD2-8698-B39F90E226ABQ38809767-91220F92-E896-4BCE-8F36-5F1BAFF50CE6Q38830910-8A882831-8753-4B3E-BD16-B3FC3959F9DCQ39071799-DCE8F0F6-1BE2-469A-93E8-0BEA7A6068F8Q39097052-4417184C-4306-4BEF-AC06-A3FDC337B037Q39183553-BF5B344F-2BAB-4D07-840F-BEEE9E1C9812Q39358458-53509BEC-C412-44B6-9158-B5A92E5F0206Q39684339-948BBD8B-E707-4D5E-B727-F219926126EBQ39873910-87BECEDA-7589-416C-A7A7-B2D59E4DE6EAQ40049558-2DB97E81-853A-421F-B728-92DDAB851309Q40598190-512B5760-D3F1-4AA4-A8A4-E6EEC8F25A99Q40608466-E8CCECC4-5754-4539-B49D-1549E2F34EDAQ40837156-E89318A6-DA02-4123-A3FA-3AB441CB3E01Q42474327-FFAB95DC-9376-4961-A48F-1DB05274ECD3Q42822378-888CDBA6-665E-4CB1-8803-D19F1EA76705Q43113975-18BB7B99-691D-4F92-91FD-E0EF5C445B5CQ43720153-AE783132-6E6A-4EA9-B282-22FAADD845DF
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Christine E Staatz
@nl
Christine E Staatz
@sl
Christine E. Staatz
@en
Christine E. Staatz
@es
type
label
Christine E Staatz
@nl
Christine E Staatz
@sl
Christine E. Staatz
@en
Christine E. Staatz
@es
prefLabel
Christine E Staatz
@nl
Christine E Staatz
@sl
Christine E. Staatz
@en
Christine E. Staatz
@es
P106
P1153
6602455628
P21
P31
P496
0000-0002-4595-9376